A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-02 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Acetamide (systematic name: ethanamide) is an organic compound with the formula CH3CONH2. It is an amide derived from ammonia and acetic acid. It finds some use as a plasticizer and as an industrial solvent. The related compound N,N-dimethylacetamide (DMA) is more widely used, but it is not prepared from acetamide. Acetamide can be considered an intermediate between acetone, which has two methyl (CH3) groups either side of the carbonyl (CO), and urea which has two amide (NH2) groups in those locations. Acetamide is also a naturally occurring mineral with the IMA symbol: Ace.
The most diverse and richest forests are the mixed-mesophytic or medium-moisture types, which are largely confined to rich, moist montane soils of the southern and central Appalachians, particularly in the Cumberland and Allegheny Mountains, but also thrive in the southern Appalachian coves. Characteristic canopy species are white basswood (Tilia heterophylla), yellow buckeye (Aesculus octandra), sugar maple (Acer saccharum), American beech (Fagus grandifolia), tuliptree (Liriodendron tulipifera), white ash (Fraxinus americana) and yellow birch (Betula alleganiensis). Other common trees are red maple (Acer rubrum), shagbark and bitternut hickories (Carya ovata and C. cordiformis) and black or sweet birch (Betula lenta ). Small understory trees and shrubs include paw paw (Asimina tribola), flowering dogwood (Cornus florida), hophornbeam (Ostrya virginiana), witch-hazel (Hamamelis virginiana) and spicebush (Lindera benzoin). There are also hundreds of perennial and annual herbs, among them such herbal and medicinal plants as American ginseng (Panax quinquefolius), goldenseal (Hydrastis canadensis), bloodroot (Sanguinaria canadensis) and black cohosh (Cimicifuga racemosa). The foregoing trees, shrubs, and herbs are also more widely distributed in less rich mesic forests that generally occupy coves, stream valleys and flood plains throughout the southern and central Appalachians at low and intermediate elevations.
Like ethylene glycol and propylene glycol, glycerol is a non-ionic kosmotrope that forms strong hydrogen bonds with water molecules, competing with water-water hydrogen bonds. This interaction disrupts the formation of ice. The minimum freezing point temperature is about −38 °C (−36 °F) corresponding to 70% glycerol in water. Glycerol was historically used as an anti-freeze for automotive applications before being replaced by ethylene glycol, which has a lower freezing point. While the minimum freezing point of a glycerol-water mixture is higher than an ethylene glycol-water mixture, glycerol is not toxic and is being re-examined for use in automotive applications. In the laboratory, glycerol is a common component of solvents for enzymatic reagents stored at temperatures below 0 °C (32 °F) due to the depression of the freezing temperature. It is also used as a cryoprotectant where the glycerol is dissolved in water to reduce damage by ice crystals to laboratory organisms that are stored in frozen solutions, such as fungi, bacteria, nematodes, and mammalian embryos. Some organisms like the moor frog produce glycerol to survive freezing temperatures during hibernation.
=== Criticism of expert witnesses === Several medical experts have questioned the reliability of the prosecution's expert witness, Dewi Evans. Svilena Dimitrova, an NHS consultant neonatologist, and Roger Norwich, a medico-legal expert, submitted formal complaints to the General Medical Council regarding Evans's evidence. Dimitrova told The Guardian that she believed "the theories proposed in court were not plausible and the prosecution was full of medical inaccuracies", adding that while she could not assert Letby's innocence, she saw "no proof of guilt". Evans rejected suggestions of bias and noted that the defence could have called its own expert witnesses at trial but did not do so. Other prosecution experts broadly supported Evans' conclusions. The New Yorker reported that in an unrelated earlier case, a Court of Appeal judge had described one of Evans's expert reports as "worthless", containing opinions that were "tendentious and partisan" and outside his professional competence. Another paediatrician who testified as an expert for the prosecution has since resigned from her position as a consultant following multiple complaints about her practice. The prosecution's endocrinologist, Peter Hindmarsh, was under investigation by the General Medical Council (GMC) when he gave evidence during the trial. The investigation was prompted by "multiple and wide-ranging concerns" about his practice from both of the hospitals he was affiliated with. A medical tribunal placed restrictions on his ability to practise, arguing that he "may pose a real risk to members of the public".
Sources: en.wikipedia.org
She gained information about nine people, including the names of four of those killed, and found that some of "the dead men had indeed been running drugs but were not narco-terrorists ... or leaders of a cartel or gang". People interviewed by Garcia Cano said most of those killed were first-time crew members, and that they "included a fisherman, a motorcycle taxi driver, laborers and two low-level career criminals ... One was a well-known local crime leader who had agreed to work for narcotics smugglers." One reportedly trafficked both drugs and humans. Two unidentified bodies suspected by locals to be casualties from the 1 September strike washed up on the shores of Trinidad and Tobago, showing signs of having been blown up. People who knew him claimed one of the bodies was a Venezuelan, recognizable by his watch; the Associated Press report said "he had been jailed by Venezuelan authorities on human-trafficking charges after a boat he had operated capsized in December 2020" and people had described him as "a longtime local crime boss [who] made most of his living smuggling drugs and people across borders". Two days after the 6 November 2025 strike, a boat matching the one in the video of the strike washed ashore in the Guajira Peninsula of northwestern Colombia, near the Gulf of Venezuela, followed by bodies and charred debris, according to The New York Times. Two bodies that washed ashore were later buried by locals but, due to the remoteness of the area, did not come to media attention until the 29 December Times report.
== Nanofactories == A nanofactory is a proposed system in which nanomachines (resembling molecular assemblers, or industrial robot arms) would combine reactive molecules via mechanosynthesis to build larger atomically precise parts. These, in turn, would be assembled by positioning mechanisms of assorted sizes to build macroscopic (visible) but still atomically-precise products. A typical nanofactory would fit in a desktop box, in the vision of K. Eric Drexler published in Nanosystems: Molecular Machinery, Manufacturing and Computation (1992), a notable work of "exploratory engineering". During the 1990s, others have extended the nanofactory concept, including an analysis of nanofactory convergent assembly by Ralph Merkle, a systems design of a replicating nanofactory architecture by J. Storrs Hall, Forrest Bishop's "Universal Assembler", the patented exponential assembly process by Zyvex, and a top-level systems design for a 'primitive nanofactory' by Chris Phoenix (director of research at the Center for Responsible Nanotechnology). All of these nanofactory designs (and more) are summarized in Chapter 4 of Kinematic Self-Replicating Machines (2004) by Robert Freitas and Ralph Merkle. The Nanofactory Collaboration, founded by Freitas and Merkle in 2000, is a focused, ongoing effort involving 23 researchers from 10 organizations and 4 countries that is developing a practical research agenda specifically aimed at positionally-controlled diamond mechanosynthesis and diamondoid nanofactory development.
=== Controversies === The FDA authorized use of injectable naltrexone (Vivitrol) for opioid addiction using a single study that was led by Evgeny Krupitsky at Bekhterev Research Psychoneurological Institute, St Petersburg State Pavlov Medical University, St Petersburg, Russia, a country where opioid agonists such as methadone and buprenorphine are not available. The study was a "double-blind, placebo-controlled, randomized", 24-week trial running "from July 3, 2008, through October 5, 2009" with "250 patients with opioid dependence disorder" at "13 clinical sites in Russia" on the use of injectable naltrexone (XR-NTX) for opioid dependence. The study was funded by the Boston-based biotech Alkermes firm which produces and markets naltrexone in the United States. Critics charged that the study violated ethical guidelines since it compared the formulation of naltrexone not to the best available, evidence-based treatment (methadone or buprenorphine), but to a placebo. Further, the trial did not follow patients who dropped out of the trial to evaluate subsequent risk of fatal overdose, a major health concern. Subsequent trials in Norway and the US did compare injectable naltrexone to buprenorphine and found them to be similar in outcomes for patients willing to undergo the withdrawal symptoms required before naltrexone administration. Nearly 30% of patients in the US trial did not complete induction.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.